US 12,070,469 B2
IP and IP analogs dosage regimens for the treatment of ectopic calcifications
Joan Perello Bestard, Palma de Mallorca (ES); Carolina Salcedo Roca, Palma de Mallorca (ES); and Ana-Zeralda Canals Hamann, Palma de Mallorca (ES)
Assigned to SANIFIT THERAPEUTICS S.A., Palma de Mallorca (ES)
Filed by SANIFIT THERAPEUTICS S.A., Palma de Mallorca (ES)
Filed on Mar. 4, 2021, as Appl. No. 17/192,609.
Application 17/192,609 is a division of application No. 16/791,808, filed on Feb. 14, 2020, granted, now 10,973,838.
Application 16/791,808 is a continuation of application No. PCT/IB2018/057904, filed on Oct. 11, 2018.
Claims priority of application No. P201830988 (ES), filed on Oct. 11, 2018.
Prior Publication US 2021/0290642 A1, Sep. 23, 2021
Int. Cl. A61K 31/7024 (2006.01); A61K 9/00 (2006.01); A61K 31/661 (2006.01); A61K 31/6615 (2006.01); A61K 31/7032 (2006.01); A61P 9/00 (2006.01); A61P 17/02 (2006.01); A61P 19/08 (2006.01)
CPC A61K 31/7024 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/6615 (2013.01); A61K 31/7032 (2013.01); A61P 9/00 (2018.01); A61P 17/02 (2018.01); A61P 19/08 (2018.01)] 26 Claims
 
1. A method to treat or inhibit the occurrence of critical limb ischemia and/or the consequences thereof in a subject comprising administering a dose of SNF472 (hexasodium salt of myo-inositol hexaphosphate) in a dosage of about 5 mg of SNF472 per kg per day to about 10 mg of SNF472 per kg per day to the subject for about 2,3,4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or 32 weeks, wherein the administration of the dosage effectively treats or inhibits the occurrence of critical limb ischemia and/or the consequences thereof in the subject.